# BRITISH JOURNAL OF RHEUMATOLOGY

The Official Journal of the British Society for Rheumatology

Order your
FREE
sample copy now.

From-January 1992 this leading, international journal will be published monthly.

Editor **H.A. Bird** (University of Leeds, UK)

Assistant Editors
D.L. Scott
M. Walport

Due to its popularity and the high number of quality papers to be published, the *British Journal of Rheumatology*, one of the leading rheumatology journals in the world, will be published **monthly** from 1992

Along with the increased number of issues the journal will also feature **two new series**.

The first starting in January 1992 is a series of **bimonthly scholarly scientific review articles** masterminded by Mark Walport, providing invaluable information for rheumatologists seeking to expand their knowledge. This will alternate with the **series of 'grand rounds'** or **clinico-pathologic conferences** devised by David Scott. **Distinguished experts** will be presented with a complex clinical problem and invited to provide critical comment.

The journal also regularly features two editorials, preliminary and brief papers, case reports, view points, practical, clinical articles, clinical conundrums, book reviews and a vigorous correspondence column. Supplements devoted to specific topics or symposia also appear once or twice a year - free of charge.

**New Monthly Editions!** 

Rapid and Up to Date Publication!

New Scientific Review Series

New Series of Grand Clinical Rounds

International Coverage

No Page Charges!

**Original Articles** 

Published by Baillière Tindall

### FORTHCOMING PAPERS

Should disease-modifying agents be used in mild rheumatoid arthritis? *M.J. Davis, P.T. Dawes, P.D. Fowler, S. Clarke, J. Fisher and M.F. Shadforth (UK).* Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of CD7 monoclonal antibody. *B.W. Kirkham, C. Pitzalis, G.H. Kingsley, I.C. Chikanza S. Sabharwal, C. Barbatis, R. Grahame, T. Gibson, P.L. Amlot and G.S. Panayi (UK).* Hand and upper limb problems of instrumental musicians. *C.M. Lambert (UK).* 

Publication:
Volume 31, 1992, 12 issues
Subscription Rate:
£125.00(UK only)/
US\$220.00(Overseas)
\*A.C.R. / EULAR Members
Rate: US\$99.00

BRITISH JOURNAL OF RHEUMATOLOGY ISSN 0263-7103	Send orders to:
Publication: Volume 31, 1992, 12 issues Subscription Rate: £125.00(UK only)/US\$220.00(Overseas)	Journals Marketing Dept. Harcourt Brace Jovanovich Ltd. 24-28 Oval Rd. London NW1 7DX, U.K.
*ACR/EULAR Members Rate: US\$99.00  Please enter my subscription for Volume 31, 1992, 12 issues.  Please send me a sample copy.  I enclose a cheque for (payable to 'Harcourt Brace Jovanovich Ltd.').  I wish to pay by Diners Club/American Express/Visa/MasterCard (delete as approp	Journals Promotion Dept. Academic Press Inc. 1250 Sixth Ave. San Diego, CA 92101, U.S.A. priate). Amount
Card Number MasterCard users should add the numbers appearing above the	Expiry Date
Signature Name (Capitals)	
(Your signature is essential, especially when paying by credit card)	
Address	
·	Date
*The member subscription rate is available only on orders placed directly with the Publisher and proof of membership may be required.	paid for out of personal funds.

## NAPRATEC<sup>TM</sup> (naproxen and misoprostol combination pack) Abbreviated Prescribing Information Uses:

Uses: For patients who require naproxen 500mg b.d. to treat rheumatoid- or osteo-arthritis or ankylosing spondylitis and Cytotec 200mcg b.d. to prevent NSAID-induced gastroduodenal ulceration Dosage:

One tablet of naproxen and one tablet of Cytotec twice daily with

### Contraindications

Pregnant women, women planning a pregnancy, breast feeding women, hypersensitivity recting women, hypersensity ity naproven, naproven sodium or prostaglandins, aspirin, anti-inflammators, induced allergy. As a prevention pack Napratec should not be used in patients with active gastroduodenal.

### Warnings Precautions

Warnings Precautions: Pre-menopausal women should use effective contraception and be advised of the risks of taking the products if pregnant NSAIDs decrease platelet aggregation and prolong bleeding time Use with care in patients with Use with care in patients with impaired renal and hepatic function, compromised cardiac function, in those with asthma or allergic disease and in disease states where hypotension might precipitate severe complications Caution is required it any of the following are administered concurrently hydantoins, anti-coagulants or highly protein bound sulphonamides, diuretics, beta blockers, lithium, probenecid, methorrevate.

### methotrexate. Naproxen adverse effects:

GI - nausea, vomiting, abdominal discomfort, bleeding, ulceration, occasionally colitis. The inclusion of Cytotec in the combination pack is to prevent naproven-induced gastric and duodenal

ulceration. CNS - headache, insomnia inability to concentrate and cognitive dysfunction.

Dematological hypersensitivity cognitive dystriction. Dermatidiantal Impersensitivituskin rashes, urticaria, angio-ocdema, rarely anaphylactic reactions, cosmophilic pneumonitis, alopecia, crythema multiforme, Stevens Johnson syndrome, epidermal necrolysis, photosensitivity reactions. Haematological—thrombocytopenia, aplastic anaemia, haemolytic anaemia. Other—tinnitus, hearing impairment, vertigo, mild peripheral ocdema, rarely jaundice, fatal hepatitis, nephropathy, haematuria, visual disturbances, vasculitis, ulcerative stomatitis.

ulcerative stomatitis

## Cytotec adverse effects: GI – diarrhoea, abdominal pain, dyspepsia, flatulence, nausea,

dyspepsia, flatuence, nausea, vomiting Female reproductive – menorrhagia, vaginal bleeding, intermenstrual bleeding, Other – skin rashes, infrequently dizziness

dizziness
Presentation:
Combination pack containing 56 tablets of naproxen 500mg and 56 tablets of Cytotec 200meg.
PL0020-0190, I v Napratec OP El800, (28 days treatment). Data sheet with full prescribing information available on request.

### SEARLE


Searle, P.O. Box 53 Lane End Road, High Wycombe Bucks HPI2 4HI

## Naproxen with peace of mind



Softens the impact of naproxen on the stomach

# ear Choice



## Clinical Rheumatology

The Journal that has the most relevance to your work.

Stimulating editorials, research articles, case reports and lively correspondence about things that interest you and often apply to your practice.

Complete the coupon below and subscribe now.

# Please enter my 1993 subscription to The Journal of Rheumatology

Reduced rates for Trainees: \$50.00 per calendar year with accompanying letter from supervisor

Rates per calendar year Individuals: \$140.00 Institutions: \$160.00

Airmail Add \$70.00 Back issues available at \$20.00 per issue when in stock.

A major supplement (when published) is included with each subscription. Any supplements are included with the price.

PROVINCE ADDRESS POSTAL CODE CITY BILL ME COUNTRY FAX NUMBER AMOUNT ENCLOSED \$ TELEPHONE NUMBER VISA # Mail completed form to: The Journal of Rheumatology EXPIRY 1051 Clinton St., Buffalo, NY 14206 SIGNATURE

All subscriptions are for 1 calendar year. Subscriptions after May will be charged an additional \$5.00 per back issue. SUBSCRIBE NOW!

### **Clinical and Experimental**

# RHEUMATOLOGY

An independent, international journal conveying the latest in the field of rheumatology

**Editors:** Stefano Bombardieri, *MD* (*Chief*) (*Italy*), Barbara M. Ansell, *MD* (*UK*), Graham R.V. Hughes, *MD* (*UK*), Haralampos M. Moutsopoulos, *MD* (*Greece*), Paul E. Phillips, *MD* (*USA*)

Published bi-monthly, together with supplements dedicated to international meetings and workshops, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is directed to both clinicians and experimentalists in the field of the rheumatic diseases. Through its *Original Articles, Editorials, Rapid Papers, Reviews, Case Reports* and *Letters* it reports the latest developments in important areas.

In addition, our journal was the first in its field to introduce a regular section on **Pediatric Rheumatology**. The editor of this section is **Dr. Barbara M. Ansell**.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY does not represent the official organ of any professional society. As such, we are proud of its truly international profile - our articles present a nicely balanced view of the latest research coming from groups all over the world, with national contributors accounting for less than 20% of the total. The journal's editorial board includes more than 80 internationally known specialists from around the world. They, together with our outside referees, play a central role in maintaining our high standards. Every work submitted to us is forwarded to 3 referees coming from at least two different countries. In this way, a fair screening of the articles submitted for publication is guaranteed.

Senior Editors:
Giampiero Pasero (Italo)
Vincenzo Pipitone (Italo)
Graham R.V. Hughes (U.K.)
Haralampea M. Mostopoulus (Greec)
Paul E. Phillips (U.S.A.)

ISSN 0492-456X


CLINICAL AND	Experimental <b>R</b>	HEUMATOLOGY	
via S.	Maria 31, 56126 Pisa	a, Italy	
tel: (50) 40124	Fa	Fax: (50) 553.444	
Please enter my subsc plus supplements).	•	•	
_	<u>Europe</u>	Other countries	
☐ Individual	Lit. 100.000	\$95/\$120*	
☐ Institutional	Lit. 120.000	\$120/\$155*	
☐ In-training**	Lit. 45.000	\$45	
☐ Check enclosed (paya ☐ Please charge to my ( American Express /	,	cle one):	
		predict y Burocurd	
credit card no.		expiration date	
	Last Name		
credit card no.  First Name  Professional address:	Last Name	expiration date	
First Name	Last Name	expiration date	

Advance payment is required. Rates include supplements and postage. Issues will be sent overseas by surfact mail (\*the higher rate reflects the surcharge for air mail

Back issues are available at US\$25 per issue (plus \$5 for postage overseas). Payments from abroad must be made by international cheque or credit card.

Individual subscriptions must be in the name of and paid for by the individual \*\*Students, trainees and fellows must include a letter from their supervisor.

postage overseas).



# Is early joint damage acceptable in today's RA patient?

with Rheumatoid Arthritis with Rheumatoid Arthritis with a gifer erosive Joint damage within 2 years of symptom onset offering a relatively narrow window of opportunity when disease modifying treatment can achieve most.<sup>1</sup>

Today, our potential to suppress early joint damage in RA is highlighted by the results of a recent trial. In this double-blind, randomised study in patients of median disease duration less than 9 months a

significant slowing of joint damage was evident with Salazopyrin EN-tabs compared with bydroxychloroquine at 24 and 48 weeks.<sup>2</sup> Furthermore, the difference was still significant at 3-year follow-up.<sup>3</sup> In the words of the authors, "the first blow is half the battle".<sup>3</sup>

Radiographic progression in patients treated with Salazopyrin EN-tabs or hydroxychloroquine. 2,3

4 (p < 0.02)

Joint damage (Median total radiographic scores)

30-20-10

Salazopyrin EN-tabs (n = 27)

Salazopyrin EN-tabs (n = 22)

6 12 18 24 30 36 42 Months

When NSAIDs alone fail to preserve function and mobility

## Salazopyrin® EN-tabs enteric coated sulphasalgzine

Today's choice to preserve tomorrow's lifestyle

100 A

Land Control of the State of th